Lincoln National Corp trimmed its holdings in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Get Rating) by 28.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 155,700 shares of the company’s stock after selling 62,000 shares during the period. Lincoln National Corp owned about 0.09% of Lineage Cell Therapeutics worth $182,000 at the end of the most recent reporting period.
Several other institutional investors have also added to or reduced their stakes in LCTX. JPMorgan Chase & Co. raised its stake in shares of Lineage Cell Therapeutics by 44.1% during the first quarter. JPMorgan Chase & Co. now owns 1,849,662 shares of the company’s stock valued at $2,849,000 after acquiring an additional 566,385 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Lineage Cell Therapeutics by 5.4% during the first quarter. Charles Schwab Investment Management Inc. now owns 332,406 shares of the company’s stock valued at $512,000 after acquiring an additional 17,052 shares during the last quarter. State Street Corp raised its stake in shares of Lineage Cell Therapeutics by 1.5% during the first quarter. State Street Corp now owns 2,105,107 shares of the company’s stock valued at $3,242,000 after acquiring an additional 30,873 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Lineage Cell Therapeutics by 29.2% during the first quarter. Goldman Sachs Group Inc. now owns 127,432 shares of the company’s stock valued at $196,000 after acquiring an additional 28,773 shares during the last quarter. Finally, Wealth Architects LLC bought a new position in shares of Lineage Cell Therapeutics during the first quarter valued at about $25,000. 38.11% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Separately, HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Lineage Cell Therapeutics in a research note on Friday, March 10th.
Lineage Cell Therapeutics Stock Down 1.4 %
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Get Rating) last released its quarterly earnings results on Thursday, March 9th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.03). The company had revenue of $1.92 million during the quarter, compared to the consensus estimate of $2.97 million. Lineage Cell Therapeutics had a negative net margin of 178.69% and a negative return on equity of 33.24%. On average, equities analysts anticipate that Lineage Cell Therapeutics, Inc. will post -0.17 earnings per share for the current fiscal year.
About Lineage Cell Therapeutics
Lineage Cell Therapeutics, Inc operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company’s programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery.
Featured Stories
- Get a free copy of the StockNews.com research report on Lineage Cell Therapeutics (LCTX)
- Thinking Of Buying The Dip On JD.com? Consider This First
- Wynn Resorts: A Winning Bet for 2023
- A Royally Good Time To Buy The Walt Disney Company
- 3 Surprising Stocks Leading Growth Over Value
- Copa Holdings Is Looking For A Comeback, Its Dividend Agrees
Want to see what other hedge funds are holding LCTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Get Rating).
Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
